Program
Deuruxolitinib
Also written as “CTP-543”, “[14C]-CTP-543” and “CTP-543, 16 mg (2 x 8 mg tablet)”.
Its studies are mostly in Alopecia Areata · Renal Insufficiency, led by Sun Pharmaceutical Industries.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | 233 open or running | phase 3since Mar 29, 2019 | May 16, 2016 | May 2027phase 3 · NCT03898479 |
Also a collaborator on its studies: Celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 16, 2016.
- May 6, 2019Phase 2 study in Alopecia AreataNCT03941548 · 66 enrolled · United States, Canada
- Sep 5, 2019Phase 1 study in Healthy VolunteersNCT04092712 · 6 enrolled · United States
- Mar 11, 2020Phase 1 study in Healthy VolunteersNCT04309643 · 21 enrolled · United States
- Aug 16, 2020Phase 3 study in Alopecia AreataNCT04518995 · 706 enrolled · United States, Canada, France and more
- Feb 4, 2021Phase 1 study in Healthy VolunteersNCT04743414 · 22 enrolled · United States
- Mar 3, 2021Phase 2 study in Alopecia AreataNCT04784533 · 317 enrolled · United States
- Mar 10, 2021Phase 3 study in Alopecia AreataNCT04797650 · 517 enrolled · United States, Canada, France and more
- Apr 9, 2021Phase 1 study in Healthy VolunteersNCT04843540 · 22 enrolled · United States
- Sep 3, 2021Phase 3 study in Alopecia AreataNCT05041803 · 407 enrolled · France, Germany, Hungary and more
- Jan 5, 2022Phase 1 study in Healthy VolunteersNCT05192369 · 48 enrolled · United States
- Jun 30, 20224 phase 1 studiesNCT05468749, NCT05467722, NCT05467709 and 1 more
- Jul 26, 2022Phase 1 study in Health VolunteersNCT05478772 · 18 enrolled · United States
- Jul 29, 2025Phase 3 study in Alopecia AreataNCT07133308 · 355 planned · United States, Canada
- May 22, 2026Phase 3 study in Alopecia AreataNCT07617597 · 78 planned · Japan
Ahead
- May 2027Primary completion: phase 3 study in Alopecia AreataNCT03898479
- Feb 2028Primary completion: phase 3 study in Alopecia AreataNCT07617597
- May 2028Primary completion: phase 3 study in Alopecia AreataNCT07133308
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07617597Alopecia Areata · Japan | 3 | Recruiting | Feb 2028 | 78 |
| NCT07133308Alopecia Areata · United States, Canada | 3 | Recruiting | May 2028 | 355 |
| NCT05478772Health Volunteers · United States | 1 | Completed | Aug 6, 2022 | 18 |
| NCT05468749Renal Insufficiency · United States | 1 | Completed | Oct 20, 2022 | 16 |
| NCT05467722Hepatic Impairment · United States | 1 | Completed | Sep 15, 2022 | 21 |
| NCT05467709Health Volunteers · United States | 1 | Completed | Jun 30, 2022 | 20 |
| NCT05467696Health Volunteers · United States | 1 | Completed | Jun 26, 2022 | 16 |
| NCT05192369Healthy Volunteers · United States | 1 | Completed | Jan 28, 2022 | 48 |
| NCT05041803Alopecia Areata · France, Germany, Hungary and more | 3 | Completed | Jul 18, 2024 | 407 |
| NCT04843540Healthy Volunteers · United States | 1 | Completed | Jun 24, 2021 | 22 |
| NCT04797650Alopecia Areata · United States, Canada, France and more | 3 | Completed | Jun 8, 2022 | 517 |
| NCT04784533Alopecia Areata · United States | 2 | Completed | May 16, 2023 | 317 |
| NCT04743414Healthy Volunteers · United States | 1 | Completed | Mar 27, 2021 | 22 |
| NCT04518995Alopecia Areata · United States, Canada, France and more | 3 | Completed | Apr 19, 2022 | 706 |
| NCT04309643Healthy Volunteers · United States | 1 | Completed | Jun 25, 2020 | 21 |
| NCT04092712Healthy Volunteers · United States | 1 | Completed | Sep 11, 2019 | 6 |
| NCT03941548Alopecia Areata · United States, Canada | 2 | Completed | Apr 10, 2020 | 66 |
| NCT03898479Alopecia Areata · United States, Canada | 3 | Active, not recruiting | May 2027 | 1,000 |
| NCT03880136Healthy · United States | 1 | Completed | Apr 5, 2019 | 14 |
| NCT03811912Alopecia Areata · United States | 2 | Completed | Nov 21, 2019 | 57 |
| NCT03137381Alopecia Areata · United States | 2 | Completed | Jul 8, 2019 | 149 |
| NCT02960945Healthy · United States | 1 | Completed | Jan 2017 | 12 |
| NCT02777008Healthy · Australia | 1 | Completed | Dec 2016 | 77 |
How it is read
Names in the registry
- “CTP-543”, 21 entries
- “Deuruxolitinib”, 2 entries
- “[14C]-CTP-543”, 1 entry
- “CTP-543, 16 mg (2 x 8 mg tablet)”, 1 entry
Conditions, from the studies’ own filings
- Alopecia Areata, 10 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.